ReviewCancer immunology, immunotherapy : CII2005
Immunotherapy for superficial bladder cancer.
Review in Cancer immunology, immunotherapy : CII, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 67 citations in OpenAlex.
- ZSTK474 suppresses bladder cancer cell migration and invasion via PI3K/Akt/Girdin pathway: an in vitro study.International urology and nephrology · 2026Article
- Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance.PloS one · 2026Article
- Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.International journal of molecular sciences · 2020Review
- Combined lectin- and immuno-histochemistry (CLIH) for applications in cell biology and cancer diagnosis: Analysis of human urothelial carcinomas.European journal of histochemistry : EJH · 2020Article
- Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer.Cancer science · 2019Article
- Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.Oncology letters · 2018Article
- Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.American journal of clinical and experimental urology · 2018Article
- Article
- Methotrexate-coupled nanoparticles and magnetic nanochemothermia for the relapse-free treatment of T24 bladder tumors.International journal of nanomedicine · 2017Article
- Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness.Oncotarget · 2016Article
- LocalOncoimmunology · 2015Article
- Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo.Journal of experimental & clinical cancer research : CR · 2015Article
- NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.Purinergic signalling · 2014Article
- Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models.Protoplasma · 2014Article
- The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.International journal of molecular sciences · 2013Article
- Heterogeneity of uroplakin localization in human normal urothelium, papilloma and papillary carcinoma.Radiology and oncology · 2013Article
- Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.Oncoimmunology · 2012Article
- Article
- Genetic susceptibility to bladder cancer risk and outcome.Personalized medicine · 2011Article
- XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.Journal of cancer research and clinical oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of superficial bladder cancer requires adjuvant therapies besides transurethral resection because of a high recurrence rate after this standard treatment alone. Current adjuvant therapies involve intravesical chemotherapy for patients at low and intermediate risk for recurrence and progression, and intravesical bacillus Calmette-Guérin for patients at intermediate and high risk. However, these adjuvant therapies fail in a significant number of patients, dictating the need for new and improved adjuvant treatment modalities for superficial bladder cancer. Immunotherapy aiming at the modulation of the immune system of the patient is a promising alternative adjuvant. This review discusses the current status of the clinical development of various immunotherapy approaches for superficial bladder cancer, including passive immunotherapy, immune stimulants, immunogene therapy and cancer vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.